Latin America Antibiotics Market

Latin America Antibiotics Market Size (2022 to 2027)

The Latin American antibiotics market size is forecasted to be growing at a healthy CAGR during the forecast period.

The easy availability and colossal adoption of generic drugs and Y-O-Y growth in the number of biotech companies investing in R&D activities to develop better valued-providing products are expected to drive the Latin American antibiotics market growth. The rising prevalence of infectious diseases such as pneumonia, HIV/AIDS, tuberculosis in Latin American countries increases the demand for antibiotics in this regional market.     

The advancements and launch of new drugs and combinations in treating people with an extensive range of bacterial infections propel the antibiotics market development in Latin America. The growing number of people suffering from infectious diseases, the latest drug approvals, and ongoing clinical trials conducted by pharmaceutical companies are further expected to boost the market's growth rate. The growth of the Latin American antibiotics market is further expected to drive by the growing number of collaborations between public and private organizations.

However, the inappropriate use of antibiotics in both developed and developing countries impedes the market growth rate slightly. Issues associated with antibiotic resistance, long and mindless regulatory processes are likely to hinder the growing adoption of antibiotics in the region.

COVID-19 impact on the Latin American antibiotics market:

The SARS-CoV-2 is the etiologic agent of the COVID-19 pandemic, one of the fatal infectious diseases. The sudden eruption of COVID-19 has caused a positive influence on the Latin American antibiotics market. Antibiotics increase life expectancy in hospitalized and critically ill patients and are safeguarding parameters for the patients. Patients with more symptoms receive antivirals, antibiotics, or both. 

This research report on the Latin American antibiotics market has been segmented and sub-segmented into the following categories.

By Action Mechanism:

• Cell Wall Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Rna Synthesis Inhibitors
• Mycolic Acid Synthesis Inhibitors
• Folic Acid Synthesis Inhibitors

By Drug Class:

• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamides
• Others

By Country:

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America

In Latin America, community-acquired infections are more antibiotic-resistant in more industrialized countries. Y-O-Y rise in the number of bacterial infections and growing pressure of these diseases are key growth drivers.

Among various nations of Latin America, the Brazilian antibiotics market is predicted to dominate this regional market due to the highest consumption rate of antibiotics. In October 2010, the Brazilian National Health Surveillance issued an Administrative Act, has implemented the allotment of antibiotics prescription. In Brazil, the antibiotics can be purchased over-the-counter, leading to self-medication.

The market players in Latin America for the antibiotics market are Bayer Health care, Boehringer Ingelheim International GmbH, and Elanco contribute 50% of the majority of the share.

During the forecast period, the Mexican antibiotics market is forecasted to perform well. Antibiotics are one of the medicines sold in private pharmacies, and the use of antibiotics has exceeded in the past few years in Mexico. Y-O-Y rise in the number of hospitals with a growing patient pool drives the Mexican antibiotics market growth.

KEY MARKET PLAYERS:

Companies playing a promising role in the Latin American antibiotics market profiled in this report are Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG.